The ENGAGE study: a 3-arm randomized hybrid type 1 effectiveness and implementation study of an in-home, collaborative PCP model of remote telegenetic services to increase uptake of cancer genetic services in childhood cancer survivors

Table 2 Effectiveness outcomes and measures

CONSTRUCT	T0	T1	T2-T4
Moderators of patient outcomes
Sociodemographics	X
Cancer history	X
Family history	X
Health literacy	X
Comfort with technology	X
Self-efficacy	X
COVID Impact	X		X
Outcomes
*Uptake counsling, testing, identification carriers at 6 months* ^a (Telegenetics records for Arms A/B & the 6-Month Status Survey in Arm C)
*Understanding of Genetic Information* ^b
Test result recall			X
Knowledge of genetic disease	X	X	X
Perceived risk	X	X	X
*Reactions to genetic information* ^b
Anxiety and Depression	X	X	X
Cancer specific distress	X	X	X
Satisfaction with genetic services and telemedicine		X	X
*Behavioral use of genetic information* ^b
Performance of behaviors	X		X
Cost (patient and system)^b		X	X

T0 = baseline (within 30 days of visit 1, can accept within 45 days. beyond that it needs to be updated), waitlist usual care particiants will need to complete a new baseline, T0b; T1 = survey post pre-test counseling, Visit 1 (ideally collect 1–3 days and up to 7 days. accept up to 14 days but from 7–14 days we may elect to drop and impute). T2 = survey immediately post genetic testing disclosure (same timing as T1); T3/T4 survey = 6/12-month post genetic testing disclosure (idealy get within 14 days of 6/12 month mark but accept within 60 days of 6 month or 12 month mark)
^aAim 1
^bAim 2

ISSN: 1472-6963